Thromboxane A2 synthetase inhibitor (OKY-046) improves abnormal mucociliary transport in asthmatic patients
Affiliations
- PMID: 1736720
Item in Clipboard
Thromboxane A2 synthetase inhibitor (OKY-046) improves abnormal mucociliary transport in asthmatic patients
Ann Allergy.
1992 Jan.
Abstract
The effect of a thromboxane A2 synthetase inhibitor (OKY-046, 400 mg po/day) on mucociliary transport was investigated in 19 asthmatic patients. The nasal clearance time, as measured by the saccharin test, was prolonged in asthmatics (60.2 +/- 8.4 SE min) compared with normal controls (15.1 +/- 3.4 SE min). Within 4 weeks after OKY-046 administration, the nasal clearance time had improved (27.4 +/- 4.4 SE min, P less than .01) and the amount of sputum had decreased 30% (P less than .01). These results indicate that thromboxane A2 plays an important role in mucociliary transport in patients with asthma.
Similar articles
-
[Mucociliary transport disturbance after an asthmatic attack].Arerugi. 1990 Jul;39(7):631-5. Arerugi. 1990. PMID: 2073144 Japanese.
-
Thromboxane A2 production in allergen-induced immediate and late asthmatic responses. Its possible role in inducing the late response.J Asthma. 1988;25(3):117-24. doi: 10.3109/02770908809073198. J Asthma. 1988. PMID: 3182583
-
Inhibitory effect of a selective thromboxane synthetase inhibitor, OKY-046, on acetaldehyde-induced bronchoconstriction in asthmatic patients.Chest. 1994 Nov;106(5):1414-8. doi: 10.1378/chest.106.5.1414. Chest. 1994. PMID: 7956393 Clinical Trial.
-
[Thromboxane A2 synthetase inhibitor in asthma therapy].Nihon Rinsho. 1996 Nov;54(11):3034-9. Nihon Rinsho. 1996. PMID: 8950950 Review. Japanese.
-
[Thromboxane A2 synthase inhibitor and receptor antagonist].Nihon Rinsho. 2001 Oct;59(10):1986-91. Nihon Rinsho. 2001. PMID: 11676143 Review. Japanese.